, China
108 views

Medical device producers with advanced R&D in China to outperform peers: UOB KayHian

This is on the back of the growing availability of therapeutics and vaccines.

Some pharmaceutical firms and other research and development companies with advanced research and development on anti COVID-19 treatments and vaccines in China will outperform their peers, stemming from a demand for increasing availability of effective therapeutics and vaccines, investment banking company, UOB KayHian, said.

In its research on China’s healthcare sector, the firm sees that the strict lockdown measures will effectively mitigate the new wave of COVID-19 in China. With this, UOB KayHian pushed for increasing the availability of effective therapeutics and vaccines to improve the situation.

Due to these demands, UOB KayHian said companies with good potential for launching advanced COVID-19 treatments and vaccines will benefit and are likely to outperform.

Amongst the Chinese medical device producers that will likely become profitable are WuXi AppTec, WuXi Bio, CSPC Pharma Group, and Mindray.

UOB KayHian cited that China logged a vaccination rate of 88.1%, with 1.24 billion people receiving 3.29 billion doses of vaccines.

Follow the link for more news on

Join Healthcare Asia Magazine community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!